Core Viewpoint - Minsheng Health (301507) announced that the domestic approval for varenicline tablets was mostly obtained in recent years, and related companies have just begun sales, with scale gradually increasing [1] Group 1: Market Potential - The report from the National Health Commission indicates a large number of smokers in China, suggesting significant market space for smoking cessation drugs [1] - The market potential for varenicline in China has not been fully developed, referencing Pfizer's original drug sales performance in overseas markets [1] Group 2: Collaboration and Initiatives - The company collaborates with authoritative smoking cessation organizations to conduct public education on smoking cessation [1] - In August 2025, the company, in partnership with the China Smoking Control Association, will release the "China Clinical Smoking Control and Cessation Expert Consensus Gold Standard (2025 Updated Version)" [1] - In November 2025, the company will jointly establish a Health Promotion Professional Committee with the China Smoking Control and Health Association [1] Group 3: Commitment to Public Health - As an active participant in public health services, the company plans to collaborate with relevant authoritative institutions to promote academic research, standard formulation, and health education [1] - The company aims to contribute to the establishment of a more comprehensive smoking control system, supporting the construction of a healthy China through its pharmaceutical efforts [1]
民生健康：伐尼克兰在国内的市场潜力尚未得到充分开发，市场潜力较大